Karyopharm Therapeutics | KPTI - Cash And Equivalent


Karyopharm Therapeutics reported $60.54M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Abbott USD 6.8B 1.72B Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.7B 561M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Takeda JPY 654.94B 26.55B Dec/2025
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
TG Therapeutics USD 442.21M 242.7M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026